Stock EQL EQL PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials EQL Pharma AB

Equities

EQL

SE0005497732

Drug Retailers

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 06:00:00 2024-05-07 pm EDT 		5-day change 1st Jan Change
43.8 SEK -0.23% Intraday chart for EQL Pharma AB -0.90% +31.14%
Apr. 22 EQL Pharma AB Announces Mellozzan Launched in Germany and Austria CI
Feb. 13 EQL Pharma AB Provides Sales Guidance for the Year 2023/24 CI

Valuation

Fiscal Period: March 2023 2024 2025 2026
Capitalization 1 1,087 1,224 - -
Enterprise Value (EV) 1 1,087 1,265 1,219 1,158
P/E ratio 35.3 x 20.3 x 16 x 13.4 x
Yield - - - -
Capitalization / Revenue - 3.37 x 2.88 x 2.53 x
EV / Revenue - 3.48 x 2.87 x 2.4 x
EV / EBITDA - 13.4 x 10.8 x 8.97 x
EV / FCF - -60.2 x 27.1 x 19.3 x
FCF Yield - -1.66% 3.69% 5.18%
Price to Book - 5.03 x 4.2 x 3.57 x
Nbr of stocks (in thousands) 29,064 29,064 - -
Reference price 2 37.40 42.10 42.10 42.10
Announcement Date 5/11/23 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2023 2024 2025 2026
Net sales 1 - 363.1 424.7 483
EBITDA 1 - 94.68 112.4 129
EBIT 1 - 81.75 100.3 118
Operating Margin - 22.52% 23.62% 24.43%
Earnings before Tax (EBT) 1 - 75.23 95.54 115
Net income 1 30.92 60.03 76.32 91
Net margin - 16.53% 17.97% 18.84%
EPS 2 1.060 2.070 2.630 3.150
Free Cash Flow 1 - -21 45 60
FCF margin - -5.78% 10.6% 12.42%
FCF Conversion (EBITDA) - - 40.04% 46.51%
FCF Conversion (Net income) - - 58.97% 65.93%
Dividend per Share 2 - - - -
Announcement Date 5/11/23 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2024 Q4
Net sales -
EBITDA 1 17
EBIT 1 14
Operating Margin -
Earnings before Tax (EBT) 1 13
Net income 1 11
Net margin -
EPS 2 0.3700
Dividend per Share -
Announcement Date -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: March 2023 2024 2025 2026
Net Debt 1 - 41 - -
Net Cash position 1 - - 5 66
Leverage (Debt/EBITDA) - 0.433 x - -
Free Cash Flow 1 - -21 45 60
ROE (net income / shareholders' equity) - 28.2% 30.1% 30.9%
ROA (Net income/ Total Assets) - - - -
Assets 1 - - - -
Book Value Per Share 2 - 8.370 10.00 11.80
Cash Flow per Share - - - -
Capex 1 - 0.15 0.08 -
Capex / Sales - 0.04% 0.02% -
Announcement Date 5/11/23 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Drug Retailers

1st Jan change Capi.
EQL PHARMA AB Stock EQL Pharma AB
+31.14% 113M
WALGREENS BOOTS ALLIANCE, INC. Stock Walgreens Boots Alliance, Inc.
-34.16% 14.83B
JD HEALTH INTERNATIONAL INC. Stock JD Health International Inc.
-24.55% 12.04B
YIFENG PHARMACY CHAIN CO., LTD. Stock Yifeng Pharmacy Chain Co., Ltd.
+14.96% 6.44B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED Stock Alibaba Health Information Technology Limited
-25.24% 6.52B
MATSUKIYOCOCOKARA & CO. Stock MatsukiyoCocokara & Co.
-8.01% 6.15B
NAHDI MEDICAL COMPANY Stock Nahdi Medical Company
-2.34% 4.64B
CORPORATIVO FRAGUA, S.A.B. DE C.V. Stock Corporativo Fragua, S.A.B. de C.V.
+60.00% 4.62B
CLICKS GROUP LIMITED Stock Clicks Group Limited
-8.10% 3.93B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD. Stock DaShenLin Pharmaceutical Group Co., Ltd.
-11.16% 3.49B
Other Drug Retailers
  1. Stock Market
  2. Equities
  3. EQL Stock
  4. Financials EQL Pharma AB
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW